Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 98.68 USD 0.5% Market Closed
Market Cap: 4.7B USD
Have any thoughts about
Axsome Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one AXSM stock under the Base Case scenario is 102.99 USD. Compared to the current market price of 98.68 USD, Axsome Therapeutics Inc is Undervalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AXSM Intrinsic Value
102.99 USD
Undervaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Axsome Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AXSM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AXSM?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Axsome Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Axsome Therapeutics Inc

Provide an overview of the primary business activities
of Axsome Therapeutics Inc.

What unique competitive advantages
does Axsome Therapeutics Inc hold over its rivals?

What risks and challenges
does Axsome Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Axsome Therapeutics Inc recently?

Summarize the latest earnings call
of Axsome Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Axsome Therapeutics Inc.

Provide P/S
for Axsome Therapeutics Inc.

Provide P/E
for Axsome Therapeutics Inc.

Provide P/OCF
for Axsome Therapeutics Inc.

Provide P/FCFE
for Axsome Therapeutics Inc.

Provide P/B
for Axsome Therapeutics Inc.

Provide EV/S
for Axsome Therapeutics Inc.

Provide EV/GP
for Axsome Therapeutics Inc.

Provide EV/EBITDA
for Axsome Therapeutics Inc.

Provide EV/EBIT
for Axsome Therapeutics Inc.

Provide EV/OCF
for Axsome Therapeutics Inc.

Provide EV/FCFF
for Axsome Therapeutics Inc.

Provide EV/IC
for Axsome Therapeutics Inc.

Show me price targets
for Axsome Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Axsome Therapeutics Inc?

How accurate were the past Revenue estimates
for Axsome Therapeutics Inc?

What are the Net Income projections
for Axsome Therapeutics Inc?

How accurate were the past Net Income estimates
for Axsome Therapeutics Inc?

What are the EPS projections
for Axsome Therapeutics Inc?

How accurate were the past EPS estimates
for Axsome Therapeutics Inc?

What are the EBIT projections
for Axsome Therapeutics Inc?

How accurate were the past EBIT estimates
for Axsome Therapeutics Inc?

Compare the revenue forecasts
for Axsome Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Axsome Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Axsome Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Axsome Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Axsome Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Axsome Therapeutics Inc with its peers.

Analyze the financial leverage
of Axsome Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Axsome Therapeutics Inc.

Provide ROE
for Axsome Therapeutics Inc.

Provide ROA
for Axsome Therapeutics Inc.

Provide ROIC
for Axsome Therapeutics Inc.

Provide ROCE
for Axsome Therapeutics Inc.

Provide Gross Margin
for Axsome Therapeutics Inc.

Provide Operating Margin
for Axsome Therapeutics Inc.

Provide Net Margin
for Axsome Therapeutics Inc.

Provide FCF Margin
for Axsome Therapeutics Inc.

Show all solvency ratios
for Axsome Therapeutics Inc.

Provide D/E Ratio
for Axsome Therapeutics Inc.

Provide D/A Ratio
for Axsome Therapeutics Inc.

Provide Interest Coverage Ratio
for Axsome Therapeutics Inc.

Provide Altman Z-Score Ratio
for Axsome Therapeutics Inc.

Provide Quick Ratio
for Axsome Therapeutics Inc.

Provide Current Ratio
for Axsome Therapeutics Inc.

Provide Cash Ratio
for Axsome Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Axsome Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Axsome Therapeutics Inc?

What is the current Free Cash Flow
of Axsome Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Axsome Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Axsome Therapeutics Inc

Current Assets 479.1m
Cash & Short-Term Investments 327.3m
Receivables 124.1m
Other Current Assets 27.7m
Non-Current Assets 82.3m
PP&E 6.4m
Intangibles 60.5m
Other Non-Current Assets 15.4m
Current Liabilities 196.2m
Accounts Payable 64.3m
Accrued Liabilities 122m
Other Current Liabilities 9.9m
Non-Current Liabilities 272.4m
Long-Term Debt 183m
Other Non-Current Liabilities 89.4m
Efficiency

Earnings Waterfall
Axsome Therapeutics Inc

Revenue
338.5m USD
Cost of Revenue
-30.2m USD
Gross Profit
308.3m USD
Operating Expenses
-614.5m USD
Operating Income
-306.2m USD
Other Expenses
-4.7m USD
Net Income
-311m USD

Free Cash Flow Analysis
Axsome Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Axsome Therapeutics achieved a pivotal milestone with Q3 total net product revenue reaching $104.8 million, marking an 81% increase year-over-year. Auvelity's sales surged to $80.4 million, growing 113% compared to last year. Sunosi also showed strong performance with a 21% revenue increase to $24.4 million. The company plans to expand its sales force by 300 representatives to further enhance Auvelity's market presence. Looking ahead, Axsome anticipates significant growth driven by upcoming product launches, including AXS-07 for migraines, which is poised for FDA review by January 31, 2025. The organization remains steadfast in targeting cash flow positivity in the near future.

What is Earnings Call?
Fundamental Scores

AXSM Profitability Score
Profitability Due Diligence

Axsome Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
39/100
Profitability
Score

Axsome Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

AXSM Solvency Score
Solvency Due Diligence

Axsome Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
39/100
Solvency
Score

Axsome Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AXSM Price Targets Summary
Axsome Therapeutics Inc

Wall Street analysts forecast AXSM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AXSM is 130.69 USD with a low forecast of 71.71 USD and a high forecast of 189 USD.

Lowest
Price Target
71.71 USD
27% Downside
Average
Price Target
130.69 USD
32% Upside
Highest
Price Target
189 USD
92% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AXSM?

Click here to dive deeper.

Dividends

Axsome Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AXSM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AXSM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

AXSM News

Other Videos

Profile

Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

4.8B USD

Dividend Yield

0%

Description

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 108 full-time employees. The company went IPO on 2015-11-19. The firm is engaged in developing therapies for the management of central nervous system (CNS) disorders. The firm's core CNS portfolio includes four CNS product candidates, AXS-05, AXS-07, AXS-12, and AXS-14, which are being developed for multiple indications. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral, rapidly absorbed and multi-mechanistic investigational medicine under development for the acute treatment of migraine. AXS-07 consists of Molecular Solubility Enhanced Inclusion Complex (MoSEIC), meloxicam and rizatriptan. AXS-12, reboxetine, is an oral, investigational medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine, is an oral, investigational medicine in development for the treatment of fibromyalgia.

Contact

NEW YORK
New York City
22 Cortlandt Street, 16Th Floor
+12123323241.0
axsome.com

IPO

2015-11-19

Employees

108

Officers

Founder, Chairman, CEO & President
Dr. Herriot Tabuteau M.D.
Chief Financial Officer
Mr. Nick Pizzie CPA, M.B.A.
Chief Operating Officer
Mr. Mark L. Jacobson M.A.
General Counsel & Secretary
Mr. Hunter Murdock Esq.
Executive VP & Head of Commercial
Mr. Ari Maizel

See Also

Discover More
What is the Intrinsic Value of one AXSM stock?

The intrinsic value of one AXSM stock under the Base Case scenario is 102.99 USD.

Is AXSM stock undervalued or overvalued?

Compared to the current market price of 98.68 USD, Axsome Therapeutics Inc is Undervalued by 4%.

Back to Top